Hepatocellular carcinoma (HCC) is a malignancy with a complex pathogenesis, course, and prognosis with increasing incidence. The most significant contributing factor to the development of HCC is the chronic process of inflammation and remodeling of the cirrhotic liver, in which the interaction between the tumor microenvironment (TME) and cancer cells plays a pivotal role. In recent years, increasing focus has been directed toward the role of platelets (PLTs) in mediating interactions between tumor cells and the TME and in the progression and spread of HCC, as well as other cancers. Due to their abundance in the bloodstream and intracellular granules rich in mediators facilitating their ability to modulate the immune system, PLTs play a significant role in carcinogenesis. In the context of HCC, the role of PLTs in the healing and regeneration processes of the liver has been recognized for some time. In recent years, there has been an increasing utilization of PLTs in prognostic models for patients with HCC. Given their role and the availability of clinical options that block PLTs’ action, clinical trials of platelet blockers in the adjunctive treatment of HCC are becoming increasingly common. However, further research, both preclinical and clinical, is necessary to fully elucidate the role of PLTs in HCC and their potential use as a therapeutic target. In this literature review, we summarize the current knowledge on PLTs in HCC and focus on their potential use in everyday clinical practice.
肝细胞癌（HCC）是一种发病机制复杂、病程多变且预后不良的恶性肿瘤，其发病率呈上升趋势。HCC发生的最重要促进因素是肝硬化肝脏的慢性炎症与重塑过程，其中肿瘤微环境（TME）与癌细胞之间的相互作用至关重要。近年来，血小板（PLTs）在介导肿瘤细胞与TME相互作用、促进HCC及其他癌症进展与转移中的作用日益受到关注。由于血小板在血液中含量丰富，且其胞内颗粒富含可调节免疫系统的介质，使其在致癌过程中发挥重要作用。在HCC背景下，血小板在肝脏修复与再生过程中的作用早已被认知。近年来，血小板在HCC患者预后模型中的应用日益增多。鉴于血小板的作用及现有可阻断其功能的临床手段，血小板抑制剂在HCC辅助治疗中的临床试验正逐渐普及。然而，仍需开展更多临床前及临床研究以全面阐明血小板在HCC中的作用及其作为治疗靶点的潜在价值。本文献综述总结了当前关于血小板在HCC中作用的研究进展，并重点探讨其在日常临床实践中的潜在应用前景。
Platelets in Hepatocellular Carcinoma—From Pathogenesis to Targeted Therapy
肿瘤(癌症)患者之家